Morgan Stanley Issues Positive Forecast for Contineum Therapeutics (NASDAQ:CTNM) Stock Price

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) had its price target raised by research analysts at Morgan Stanley from $20.00 to $21.00 in a research note issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 125.81% from the stock’s previous close. […]

Leave a Reply

Your email address will not be published.

Previous post DA Davidson Reiterates “Buy” Rating for Crane NXT (NYSE:CXT)
Next post How to Make the Most of the 2025 Silverstone Festival: 10 Unmissable Highlights